Publications by authors named "B Mahe"

Claim this Profile
S
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Cécile Tomowiak, Stéphanie Poulain, Morgane Nudel, Pierre Feugier, Charles Herbaux

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Reasons for Consultations on a French Telemedicine Platform.
Bénédicte Melot, Florian Drouet, Céline Gérard, Bérénice Mahé, Samuel Cousin

Stud Health Technol Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier

Am J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David MacDonald, Beatrice Mahe

Future Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis